Deal-Making

The companies will rely on AskBio’s Pro10 manufacturing platform to target retinal degeneration.

Deal-Making

Lonza joins the race for weight loss drugs with plans to produce an active pharmaceutical ingredient (API) for Iconovo’s intranasal biologic.

Facilities & Capacity

Sartorius and McMaster University have opened a 1,600 square-foot bioprocess research facility in Hamilton, Ontario, about 38 miles south of Toronto.

Upstream & Downstream Processing

With the graft-versus-host disease (GVHD) drug available in the US, the company and its partner Syndax prepare for a robust commercial launch.

Global Markets

Contract development and manufacturing organization (CDMO) Samsung Biologics will provide manufacturing services for the client in what it calls its ‘largest ever contract’.

Facilities & Capacity

Indian CDMO Aragen has laid out aggressive expansion plans for capacity and multi-modality services following a $100 million investment from Singapore-based private equity (PE) fund Quadria Capital.

Regulations

Approximately 20% of bioreactor runs over 30 months were rejected due to contamination issues at Sanofi’s Framingham biologics facility, according to the US FDA.

Regulations

With BIOSECURE in limbo, the US government seeks other ways to protect American interests.

Therapeutic Class

The companies will rely on AskBio’s Pro10 manufacturing platform to target retinal degeneration.

Therapeutic Class

BioProcess Insider is back with a Gen Z twist, breaking down 2025’s hottest bioprocessing trends – because the future of CGTs and GLP-1s is straight fire.

Upstream & Downstream Processing

Sartorius and McMaster University have opened a 1,600 square-foot bioprocess research facility in Hamilton, Ontario, about 38 miles south of Toronto.

Upstream & Downstream Processing

With the graft-versus-host disease (GVHD) drug available in the US, the company and its partner Syndax prepare for a robust commercial launch.